Spinraza sales lift Biogen revenues

Biogen Inc. (NASDAQ:BIIB) said Tuesday that growing sales of spinal muscular atrophy therapy Spinraza nusinersen helped the company to a 10% increase in 2018 revenues. The company also disclosed

Read the full 299 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE